Concepedia
Statistics
Publications
14
Citations
1K
H-Index
13
Active since
1985
Affiliations
Wellcome Trust(Current)
GlaxoSmithKline (United Kingdom)
University of Hertfordshire
University of Cambridge
Peter Topley is an author at Wellcome Trust specializing in immunology, oncology, and life sciences.
Publications per year
1985–2010
The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
David W. Rusnak, Karen Affleck, Stuart Cockerill et al. · PubMed · 2001 · 297 citations
Medicine, Oncology, Pharmacology +15
Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor.
LL Thomsen, J M Scott, Peter Topley et al. · PubMed · 1997 · 197 citations
Medicine, Oncology, Pharmacology +11
Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery
Lindy L. Thomsen, Peter Topley, Maria Daly et al. · Vaccine · 2004 · 105 citations
Pharmacy, Immunology, Molecular Pharmaceutics +16
Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erbB-2
Stuart Cockerill, Colin Stubberfield, Jeremy N. Stables et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 80 citations · Full text
Medicine, Medicinal Chemistry, Oncology +9
Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon
Adam Walker, Gráinne Dunlevy, D. Rycroft et al. · Protein Engineering Design and Selection · 2010 · 67 citations · Full text
Pharmacy, Immunology, Pharmacology +17
1–5 of 14